Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 235-246

  Collnot, Eva Maria ^a,b   Ali, Hussain ^b   Lehr, Claus Michael ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Crohn's disease; Nanomedicine; Nanoparticle; Oral; Ulcerative colitis

Indexed keywords

ACTIVATED MACROPHAGES; ADVERSE EFFECT; ANTI-INFLAMMATORY DRUGS; BIOPHARMACEUTICALS; CARRIER SYSTEMS; COLLOIDAL DRUG CARRIERS; CONVENTIONAL TREATMENTS; CROHN'S DISEASE; DRUG CARRIER; DRUG RELEASE; HIGH DOSE; IMMUNE MODULATORS; INFLAMMATORY BOWEL DISEASE; INTESTINAL EPITHELIUM; INTESTINAL MUCOSA; MOLECULAR COMPOUNDS; NANOPARTICULATE DRUG DELIVERY SYSTEMS; ORAL; PATHOPHYSIOLOGICAL; ULCERATIVE COLITIS;

DISEASES; DRUG DELIVERY; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

DRUG DOSAGE;

ADALIMUMAB; ALICAFORSEN; BUDESONIDE; CURCUMIN; CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; DRUG CARRIER; EUDRAGIT; GELATIN; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 10; LACTOBACILLUS CASEI EXTRACT; LIPOSOME; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MICROSPHERE; NANOCARRIER; NANOCRYSTAL; NANOPARTICLE; OLSALAZINE; ROLIPRAM; SALAZOSULFAPYRIDINE; SELENIUM; SILVER; TACROLIMUS;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHEMICAL BOND; CONTROLLED DRUG RELEASE; CROHN DISEASE; CUSHING SYNDROME; DENDRITIC CELL; DIABETES MELLITUS; DIARRHEA; DISEASE MODEL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; EMBRYOTOXICITY; ENTERITIS; ENZYME DEGRADATION; EXPERIMENTAL ANIMAL; GENE EXPRESSION; HELPER CELL; HEMATOLOGIC DISEASE; HUMAN; HYDROPHILICITY; HYPERTENSION; IMMUNE DEFICIENCY; INFECTION; INTESTINE MOTILITY; INTESTINE MUCOSA; KIDNEY DISEASE; LIPID PEROXIDATION; LIVER TOXICITY; LYMPHOMA; MACROPHAGE; MAST CELL; MEMBRANE PERMEABILITY; META ANALYSIS (TOPIC); MICROEMULSION; NATURAL KILLER CELL; NEPHROTOXICITY; NEUTROPHIL; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; OXIDATION; PANCREATITIS; PARESTHESIA; PARTICLE SIZE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RNA INTERFERENCE; TREMOR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AGENTS; DRUG CARRIERS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MODELS, ANIMAL; NANOPARTICLES; NUCLEOTIDES; POLYMERS;

EID: 84862644846     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.01.028     Document Type: Review

References (129)

1. D.K. Podolsky, Inflammatory bowel disease, N. Engl. J. Med. 347 (2002) 417-429.
2. Y. Meissner, A. Lamprecht, Alternative drug delivery approaches for the therapy of inflammatory bowel disease, J. Pharm. Sci. 97 (2008) 2878-2891.
3. B. Khor, A. Gardet, R.J. Xavier, Genetics and pathogenesis of inflammatory bowel disease, Nature 474 (2011) 307-317.
4. C. Fiocchi, Inflammatory bowel disease: etiology and pathogenesis, Gastroenterology 115 (1998) 182-205.
5. I. Koutroubakis, O.N.Manousos, S.G.Meuwissen, A.S. Pena, Environmental risk factors in inflammatory bowel disease, Hepatogastroenterology 43 (1996) 381-393.
6. P.L. Lakatos, Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J. Gastroenterol. 12 (2006) 6102-6108.
7. Y. Ogura, N. Inohara, A. Benito, F.F. Chen, S. Yamaoka, G. Nunez, Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB, J. Biol. Chem. 276 (2001) 4812-4818.
8. Y.Ogura,D.K.Bonen,N. Inohara,D.L.Nicolae, F.F. Chen, R. Ramos, H.Britton, T.Moran, R. Karaliuskas, R.H. Duerr, J.P. Achkar, S.R. Brant, T.M. Bayless, B.S. Kirschner, S.B. Hanauer, G. Nunez, J.H. Cho, A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease, Nature 411 (2001) 603-606.
9. D. Hollander, Intestinal permeability, leaky gut, and intestinal disorders, Curr. Gastroenterol. Rep. 1 (1999) 410-416.
10. K.A. Head, J.S. Jurenka, Inflammatory bowel disease Part 1: ulcerative colitis-pathophysiology and conventional and alternative treatment options, Altern. Med. Rev. 8 (2003) 247-283.
11. S.Y. Zhou, D. Fleisher, L.H. Pao, C. Li, B. Winward, E.M. Zimmermann, Intestinal metabolism and transport of 5-aminosalicylate, Drug Metab. Dispos. 27 (1999) 479-485.
12. A.K. Azad Khan, J. Piris, S.C. Truelove, An experiment to determine the active therapeutic moiety of sulphasalazine, Lancet 2 (1977) 892-895.
13. M. Campieri, New steroids and new salicylates in inflammatory bowel disease: a critical appraisal, Gut 50 (Suppl 3) (2002) III43-III46.
14. R.J. Greenstein, L. Su, A. Shahidi, S.T. Brown, On the action of 5-amino-salicylic acid and sulfapyridine on M. avium including subspecies paratuberculosis, PLoS One 2 (2007) e516.
15. A.C. Ford, C.N. Bernstein, K.J. Khan, M.T. Abreu, J.K.Marshall,N.J. Talley, P.Moayyedi, Glucocorticosteroid therapy in inflammatory bowel disease: systematic reviewand meta-analysis, Am. J. Gastroenterol. 106 (2011) 590-599.
16. S. Edsbacker, S. Jonsson, C. Lindberg, A. Ryrfeldt, A. Thalen, Metabolic pathways of the topical glucocorticoid budesonide in man, Drug Metab. Dispos. 11 (1983) 590-596.
17. S. Edsbacker, T. Andersson, Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease, Clin. Pharmacokinet. 43 (2004) 803-821.
18. P. Munkholm, E. Langholz, M. Davidsen, V. Binder, Frequency of glucocorticoid resistance and dependency in Crohn's disease, Gut 35 (1994) 360-362.
19. M. Engel, M. Neurath, New pathophysiological insights and modern treatment of IBD, J. Gastroenterol. 45 (2010) 571-583.
20. G.R. Lichtenstein, M.T. Abreu, R. Cohen, W. Tremaine, American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease, Gastroenterology 130 (2006) 940-987.
21. M. Naganuma, T. Fujii, M. Watanabe, The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease, J. Gastroenterol. 46 (2011) 129-137.
22. H. Ogata, T. Matsui, M. Nakamura, M. Iida, M. Takazoe, Y. Suzuki, T. Hibi, A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis, Gut 55 (2006) 1255-1262.
23. S.C. Ng, N. Arebi,M.A. Kamm, Medium-termresults of oral tacrolimus treatment in refractory inflammatory bowel disease, Inflamm. Bowel Dis. 13 (2007) 129-134.
24. J. Dretzke, R. Edlin, J. Round, M. Connock, C. Hulme, J. Czeczot, A. Fry-Smith, C. McCabe, C. Meads, A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease, Health Technol. Assess. 15 (2011) 1-250.
25. J.R. Philpott, P.B. Miner, Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD, Expert Opin. Biol. Ther. 8 (2008) 1627-1632.
26. U. Klotz, M. Schwab, Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease, Adv. Drug Deliv. Rev. 57 (2005) 267-279.
27. V.R. Sinha, R. Kumria, Colonic drug delivery: prodrug approach, Pharm. Res. 18 (2001) 557-564.
28. M.K. Chourasia, S.K. Jain, Polysaccharides for colon targeted drug delivery, Drug Deliv. 11 (2004) 129-148.
29. O. Carrette, C. Favier, C. Mizon, C. Neut, A. Cortot, J.F. Colombel, J. Mizon, Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease, Dig. Dis. Sci. 40 (1995) 2641-2646.
30. S.G. Nugent, D. Kumar, D.S. Rampton, D.F. Evans, Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs, Gut 48 (2001) 571-577.
31. Y. Sasaki, R. Hada, H. Nakajima, S. Fukuda, A. Munakata, Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease, Am. J. Gastroenterol. 92 (1997) 114-118.
32. J. Fallingborg, L.A. Christensen, B.A. Jacobsen, S.N. Rasmussen, Very low intraluminal colonic pH in patients with active ulcerative colitis, Dig. Dis. Sci. 38 (1993) 1989-1993.
33. S.S. Davis, J.G. Hardy, J.W. Fara, Transit of pharmaceutical dosage forms through the small intestine, Gut 27 (1986) 886-892.
34. K.-H. Yuen, The transit of dosage forms through the small intestine, Int. J. Pharm. 395 (2010) 9-16.
35. A. Gazzaniga, A. Maroni, M.E. Sangalli, L. Zema, Time-controlled oral delivery systems for colon targeting, Expert Opin. Drug Deliv. 3 (2006) 583-597.
36. J.M. Hebden, P.E. Blackshaw, A.C. Perkins, C.G. Wilson, R.C. Spiller, Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis, Aliment. Pharmacol. Ther. 14 (2000) 155-161.
37. V. Annese, G. Bassotti, G. Napolitano, P. Usai, A. Andriulli, G. Vantrappen, Gastrointestinal motility disorders in patients with inactive Crohn's disease, Scand. J. Gastroenterol. 32 (1997) 1107-1117.
38. H.L. Duthie, J.M.Watts, F.T. Dedombal, J.C. Goligher, Serumelectrolytes and colonic transfer of water and electrolytes in chronic ulcerative colitis, Gastroenterology 47 (1964) 525-530.
39. M.A. Eastwood, Colonic diverticulosis: medical and dietary management, Clin. Gastroenterol. 4 (1975) 85-97.
40. D.A. Adkin, S.S. Davis, R.A. Sparrow, I.R. Wilding, Colonic transit of different sized tablets in healthy subjects, J. Control. Release 23 (1993) 147-156.
41. J.G. Hardy, C.G. Wilson, E. Wood, Drug delivery to the proximal colon, J. Pharm. Pharmacol. 37 (1985) 874-877.
42. A. Lamprecht, U. Schafer, C.M. Lehr, Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa, Pharm. Res. 18 (2001) 788-793.
43. A.M. Dvorak, G.R. Dickersin, Crohn's disease: transmission electron microscopic studies. I. Barrier function. Possible changes related to alterations of cell coat, mucous coat, epithelial cells, and Paneth cells, Hum. Pathol. 11 (1980) 561-571.
44. A. Rubinstein, B. Tirosh, Mucus gel thickness and turnover in the gastrointestinal tract of the rat: response to cholinergic stimulus and implication for mucoadhesion, Pharm. Res. 11 (1994) 794-799.
45. T.T. Jubeh, Y. Barenholz, A. Rubinstein, Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes, Pharm. Res. 21 (2004) 447-453.
46. M. Carlson, Y. Raab, C. Peterson, R. Hallgren, P. Venge, Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion, Am. J. Gastroenterol. 94 (1999) 1876-1883.
47. C.G. Peterson, E. Eklund, Y. Taha, Y. Raab, M. Carlson, A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease, Am. J. Gastroenterol. 97 (2002) 1755-1762.
48. M.C. Allison, S. Cornwall, L.W. Poulter, A.P. Dhillon, R.E. Pounder, Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease, Gut 29 (1988) 1531-1538.
49. C.A. Seldenrijk, H.A. Drexhage, S.G. Meuwissen, S.T. Pals, C.J. Meijer, Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease, Gut 30 (1989) 484-491.
50. Y. Tabata, Y. Inoue, Y. Ikada, Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres, Vaccine 14 (1996) 1677-1685.
51. E.V. Batrakova, H.E. Gendelman, A.V. Kabanov, Cell-mediated drug delivery, Expert Opin. Drug Deliv. 8 (2011) 415-433.
52. J. Stein, J. Ries, K.E. Barrett, Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells, Am. J. Physiol. 274 (1998) G203-G209.
53. T.Y. Ma, M.A. Boivin, D. Ye, A. Pedram, H.M. Said, Mechanism of TNF-α± modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin lightchain kinase protein expression, Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G422-G430.
54. E. Harel, A. Rubinstein, A. Nissan, E. Khazanov, M. Nadler Milbauer, Y. Barenholz, B. Tirosh, Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa, PLoS One 6 (2011) e24202.
55. S. Ghosh, R. Panaccione, Review: anti-adhesion molecule therapy for inflammatory bowel disease, Ther. Adv. Gastroenterol. 3 (2010) 239-258.
56. E. Koren, V.P. Torchilin, Drug carriers for vascular drug delivery, IUBMB Life 63 (2011) 586-595.
57. E. Simone, B.S. Ding, V. Muzykantov, Targeted delivery of therapeutics to endothelium, Cell Tissue Res. 335 (2009) 283-300.
58. R. Dubey, P. Omrey, S.P. Vyas, S.K. Jain, Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis, J. Drug Target. 18 (2010) 589-601.
59. K. Mladenovska, R.S. Raicki, E.I. Janevik, T. Ristoski, M.J. Pavlova, Z. Kavrakovski, M.G. Dodov, K. Goracinova, Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles, Int. J. Pharm. 342 (2007) 124-136.
60. M. Simonoska Crcarevska, M. Glavas Dodov, K. Goracinova, Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa, Eur. J. Pharm. Biopharm. 68 (2008) 565-578.
61. M.S. Crcarevska,M.G. Dodov, G. Petrusevska, I. Gjorgoski, K. Goracinova, Bioefficacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis, J. Drug Target. 17 (2009) 788-802.
62. M. Rodriguez, J.A. Antunez, C. Taboada, B. Seijo, D. Torres, Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats, J. Pharm. Pharmacol. 53 (2001) 1207-1215.
63. Y. Krishnamachari, P.Madan, S. Lin, Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon, Int. J. Pharm. 338 (2007) 238-247.
64. N. Fukata, K. Uchida, T. Kusuda, M. Koyabu, H. Miyoshi, T. Fukui, M. Matsushita, A. Nishio, Y. Tabata, K. Okazaki, The effective therapy of cyclosporine A with drug delivery system in experimental colitis, J. Drug Target. 19 (2011) 458-467.
65. A. Lamprecht, H. Rodero Torres, U. Schafer, C.M. Lehr, Biodegradablemicroparticles as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease, J. Control. Release 69 (2000) 445-454.
66. H. Nakase, K. Okazaki, Y. Tabata, S. Uose, M. Ohana, K. Uchida, Y. Matsushima, C. Kawanami, C. Oshima, Y. Ikada, T. Chiba, Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy, J. Pharmacol. Exp. Ther. 292 (2000) 15-21.
67. H. Onishi, T. Oosegi, Y. Machida, Efficacy and toxicity of Eudragit-coated chitosan-succinyl-prednisolone conjugatemicrospheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis, Int. J. Pharm. 358 (2008) 296-302.
68. C. Mura, A. Nácher, V. Merino, M. Merino-Sanjuan, C. Carda, A. Ruiz, M. Manconi, G. Loy, A.M. Fadda, O. Diez-Sales, N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats, Int. J. Pharm. 416 (2011) 145-154.
69. H. Wachtel, Neurotropic effects of the optical isomers of the selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo, J. Pharm. Pharmacol. 35 (1983) 440-444.
70. A. Lamprecht, N. Ubrich, H. Yamamoto, U. Schafer, H. Takeuchi, C.M. Lehr, P. Maincent, Y. Kawashima, Design of rolipram-loaded nanoparticles: comparison of two preparation methods, J. Control. Release 71 (2001) 297-306.
71. A. Lamprecht, N. Ubrich, H. Yamamoto, U. Schafer, H. Takeuchi, P. Maincent, Y. Kawashima, C.M. Lehr, Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease, J. Pharmacol. Exp. Ther. 299 (2001) 775-781.
72. A. Lamprecht, H. Yamamoto, H. Takeuchi, Y. Kawashima, Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats, J. Pharmacol. Exp. Ther. 315 (2005) 196-202.
73. W.F. Finn, FK506 nephrotoxicity, Ren. Fail. 21 (1999) 319-329.
74. A. Lamprecht, H. Yamamoto, H. Takeuchi, Y. Kawashima, A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles, J. Control. Release 104 (2005) 337-346.
75. A. Lamprecht, H. Yamamoto, H. Takeuchi, Y. Kawashima, Design of pH-sensitive microspheres for the colonic delivery of the immunosuppressive drug tacrolimus, Eur. J. Pharm. Biopharm. 58 (2004) 37-43.
76. A. Lamprecht, H. Yamamoto, N. Ubrich, H. Takeuchi, P. Maincent, Y. Kawashima, FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression, Pharm. Res. 22 (2005) 193-199.
77. Y. Meissner, Y. Pellequer, A. Lamprecht, Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery, Int. J. Pharm. 316 (2006) 138-143.
78. A. Makhlof, Y. Tozuka, H. Takeuchi, pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis ratmodel, Eur. J. Pharm. Biopharm. 72 (2009) 1-8.
79. D. Pertuit, B. Moulari, T. Betz, A. Nadaradjane, D. Neumann, L. Ismaïli, B. Refouvelet, Y. Pellequer, A. Lamprecht, 5-Amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease, J. Control. Release 123 (2007) 211-218.
80. N. Mahajan, D. Sakarkar, A. Manmode, V. Pathak, R. Ingole, D. Dewade, Biodegradable nanoparticles for targeted delivery in treatment of ulcerative colitis, Adv. Sci. Lett. 4 (2011) 349-356.
81. T.T. Jubeh, M. Nadler-Milbauer, Y. Barenholz, A. Rubinstein, Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD, J. Drug Target. 14 (2006) 155-163.
82. S. Das, A. Chaudhury, Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery, AAPS PharmSciTech 12 (2011) 62-76.
83. R.H. Müller, S.A. Runge, V. Ravelli, A.F. Thünemann, W. Mehnert, E.B. Souto, Cyclosporine-loaded solid lipid nanoparticles (SLN®): drug-lipid physicochemical interactions and characterization of drug incorporation, Eur. J. Pharm. Biopharm. 68 (2008) 535-544.
84. R.H. Muller, S. Runge, V. Ravelli, W. Mehnert, A.F. Thunemann, E.B. Souto, Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals, Int. J. Pharm. 317 (2006) 82-89.
85. M. Muchow, P.Maincent, R.H.Muller, Lipid nanoparticles with a solidmatrix (SLN, NLC, LDC) for oral drug delivery, Drug Dev. Ind. Pharm. 34 (2008) 1394-1405.
86. L.J. Penkler, R.H. Muller, S.A. Runge, V. Ravelli, Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation, in, USA, 2003.
87. R.H. Muller, C.M. Keck, Challenges and solutions for the delivery of biotech drugs -a review of drug nanocrystal technology and lipid nanoparticles, J. Biotechnol. 113 (2004) 151-170.
88. T. Bekerman, J. Golenser, A. Domb, Cyclosporin nanoparticulate lipospheres for oral administration, J. Pharm. Sci. 93 (2004) 1264-1270.
89. L. Serpe, R. Canaparo, M. Daperno, R. Sostegni, G. Martinasso, E. Muntoni, L. Ippolito, N. Vivenza, A. Pera, M. Eandi, M.R. Gasco, G.P. Zara, Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model, Eur. J. Pharm. Sci. 39 (2010) 428-436.
90. F. Leonard, E.M. Collnot, C.M. Lehr, A three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro, Mol. Pharm. 7 (2010) 2103-2119.
91. Y.V. Ramshankar, S. Suresh, K. Devi, Novel self-emulsifying formulation of curcumin with improved dissolution, antiangiogenic and anti-inflammatory activity, Clin. Res. Regul. Aff. 25 (2008) 213-234.
92. K.C. Bhol, P.J. Schechter, Effects of nanocrystalline silver (NPI 32101) in a ratmodel of ulcerative colitis, Dig. Dis. Sci. 52 (2007) 2732-2742.
93. A.E. Miroliaee, H. Esmaily, A. Vaziri-Bami, M. Baeeri, A.R. Shahverdi, M. Abdollahi, Amelioration of experimental colitis by a novel nanoselenium- silymarin mixture, Toxicol. Mech. Methods 21 (2011) 200-208.
94. L. Steidler,W.Hans, L. Schotte, S.Neirynck, F.Obermeier,W. Falk,W. Fiers, E. Remaut, Treatment of murine colitis by Lactococcus lactis secreting interleukin-10, Science 289 (2000) 1352-1355.
95. K. Vandenbroucke, H. De Haard, E. Beirnaert, T. Dreier, M. Lauwereys, L. Huyck, J. Van Huysse, P. Demetter, L. Steidler, E. Remaut, C. Cuvelier, P. Rottiers, Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis, Mucosal Immunol. 3 (2010) 49-56.
96. L. Steidler, S. Neirynck, N. Huyghebaert, V. Snoeck, A. Vermeire, B. Goddeeris, E. Cox, J.P. Remon, E. Remaut, Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10, Nat. Biotech. 21 (2003) 785-789.
97. H. Laroui, G. Dalmasso, H.T.T. Nguyen, Y. Yan, S.V. Sitaraman, D. Merlin, Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model, Gastroenterology 138 (2010) 843-853.e842.
98. H. Laroui, A.L. Theiss, Y. Yan, G. Dalmasso, H.T.T. Nguyen, S.V. Sitaraman, D.Merlin, Functional TNFα gene silencing mediated by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colon, Biomaterials 32 (2011) 1218-1228.
99. A. Saadatzadeh, F. Atyabi,M.R. Fazeli, R. Dinarvand, H. Jamalifar, A.H. Abdolghaffari, P. Mahdaviani,M.Mahbod, M. Baeeri, A. Baghaei, A.Mohammadirad, M. Abdollahi, Biochemical and pathological evidences on the benefit of a new biodegradable nanoparticles of probiotic extract in murine colitis, Fundam. Clin. Pharmacol. (2011).
100. M. van de Weert, W.E. Hennink, W. Jiskoot, Protein instability in poly(lactic-coglycolic acid) microparticles, Pharm. Res. 17 (2000) 1159-1167.
101. W. Jiskoot, T.W. Randolph, D.B. Volkin, C.R. Middaugh, C. Schöneich, G. Winter, W. Friess, D.J.A. Crommelin, J.F. Carpenter, Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release, J. Pharm. Sci. (2011) n/a-n/a.
102. U. Bilati, E. Allémann, E. Doelker, Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles, Eur. J. Pharm. Biopharm. 59 (2005) 375-388.
103. G. Zhu, S.R. Mallery, S.P. Schwendeman, Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide), Nat. Biotechnol. 18 (2000) 52-57.
104. L. Blasi, S. Argentiere, G. Morello, I. Palamà, G. Barbarella, R. Cingolani, G. Gigli, Uptake and distribution of labeled antibodies into pH-sensitive microgels, Acta Biomater. 6 (2010) 2148-2156.
105. R. Gong, C. Li, S. Zhu, Y. Zhang, Y. Du, J. Jiang, A novel pH-sensitive hydrogel based on dual crosslinked alginate/N-α-glutaric acid chitosan for oral delivery of protein, Carbohydr. Polym. 85 (2011) 869-874.
106. M.D. Bhavsar, M.M. Amiji, Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease, Gene Ther. 15 (2008) 1200-1209.
107. H. Nakase, K. Okazaki, Y. Tabata, M. Ozeki, N. Watanabe, M. Ohana, S. Uose, K. Uchida, T. Nishi, M. Mastuura, H. Tamaki, T. Itoh, C. Kawanami, T. Chiba, New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease, J. Pharmacol. Exp. Ther. 301 (2002) 59-65.
108. K. Tahara, S. Samura, K. Tsuji, H. Yamamoto, Y. Tsukada, Y. Bando, H. Tsujimoto, R. Morishita, Y. Kawashima, Oral nuclear factor-kappaB decoy oligonucleotides delivery system with chitosan modified poly(D, L-lactide-co-glycolide) nanospheres for inflammatory bowel disease, Biomaterials 32 (2011) 870-878.
109. C. Kriegel, M. Amiji, Oral TNF-α gene silencing using a polymeric microspherebased delivery system for the treatment of inflammatory bowel disease, J. Control. Release (2011).
110. L. Zuo, Z. Huang, L. Dong, L. Xu, Y. Zhu, K. Zeng, C. Zhang, J. Chen, J. Zhang, Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis, Gut 59 (2010) 470-479.
111. K.J. Myers, S. Murthy, A. Flanigan, D.R.Witchell,M. Butler, S.Murray, A. Siwkowski, D. Goodfellow, K. Madsen, B. Baker, Antisense oligonucleotide blockade of tumor necrosis factor-α in two murine models of colitis, J. Pharmacol. Exp. Ther. 304 (2003) 411-424.
112. D.S. Wilson, G. Dalmasso, L. Wang, S.V. Sitaraman, D. Merlin, N. Murthy, Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines, Nat. Mater. 9 (2010) 923-928.
113. M. Aouadi, G.J. Tesz, S.M. Nicoloro, M. Wang, M. Chouinard, E. Soto, G.R. Ostroff, M.P. Czech, Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation, Nature 458 (2009) 1180-1184.
114. D. Peer, E.J. Park, Y. Morishita, C.V. Carman, M. Shimaoka, Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target, Science 319 (2008) 627-630.
115. T.T. Kararli, Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals, Biopharm. Drug Dispos. 16 (1995) 351-380.
116. S. Wirtz, M.F. Neurath, Mouse models of inflammatory bowel disease, Adv. Drug Deliv. Rev. 59 (2007) 1073-1083.
117. W. Strober, I.J. Fuss, R.S. Blumberg, The immunology of mucosal models of inflammation, in, 2002, pp. 495-549.
118. S. Murthy, A. Flanigan, Animal model of inflammatory bowel disease, in: D.W. Morgan, L.A. Marshall (Eds.) In Vivo Models of Inflammation Birkhauser Verlag AG, 1999.
119. J.C. Hoffmann, N.N. Pawlowski, A.A. Kuehl, W. Hoehne, M. Zeitz, Animal models of inflammatory bowel disease: an overview, Pathobiology 70 (2003) 121-130.
120. G. Kojouharoff, W. Hans, F. Obermeier, D.N. Mannel, T. Andus, J. Scholmerich, V. Gross, W. Falk, Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice, Clin. Exp. Immunol. 107 (1997) 353-358.
121. A. Lamprecht, IBD: selective nanoparticle adhesion can enhance colitis therapy, Nat. Rev. Gastroenterol. Hepatol. 7 (2010) 311-312.
122. E.L. McConnell, H.M. Fadda, A.W. Basit, Gut instincts: explorations in intestinal physiology and drug delivery, Int. J. Pharm. 364 (2008) 213-226.
123. Press, Hauptmann, Fuchs, Ewe, Ramadori, Gastrointestinal pH profiles in patients with inflammatory bowel disease, Aliment. Pharmacol. Ther. 12 (1998) 673-678.
124. M.A. McGuckin, R. Eri, L.A. Simms, T.H. Florin, G. Radford-Smith, Intestinal barrier dysfunction in inflammatory bowel diseases, Inflamm. Bowel Dis. 15 (2009) 100-113.
125. S. Zeissig, N. Burgel, D. Gunzel, J. Richter, J. Mankertz, U.Wahnschaffe, A.J. Kroesen, M. Zeitz, M. Fromm, J.D. Schulzke, Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease, Gut 56 (2007) 61-72.
126. R.M. Al-Sadi, T.Y. Ma, IL-1beta causes an increase in intestinal epithelial tight junction permeability, J. Immunol. 178 (2007) 4641-4649.
127. M. Ramasundara, S.T. Leach, D.A. Lemberg, A.S. Day, Defensins and inflammation: the role of defensins in inflammatory bowel disease, J. Gastroenterol. Hepatol. 24 (2009) 202-208.
128. R. Ehehalt, A. Braun, M. Karner, J. Füllekrug, W. Stremmel, Phosphatidylcholine as a constituent in the colonic mucosal barrier- physiological and clinical relevance, Biochim. Biophys. Acta 1801 (2010) 983-993.
129. P.R. Gibson, J.G. Muir, Reinforcing the mucus: a new therapeutic approach for ulcerative colitis? Gut 54 (2005) 900-903.